By Dr Diana Schuhmacher

Journal articles

Bergsma P; Porazinski S; Istadi A; Chacon-Fajardo D; Mahmood Y; Lombardi S; Schuhmacher D; Barraclough-Franks H; Strbenac D; Dennis CV; Faizi-Sobbi P; Cahill E; Bhadri VA; De Almeida Silva J; Lum T; Wykes J; Manzie T; Palme CE; Yang JYH; Clark JR; Gupta R; Pajic M, 2025, 'Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion–Defined Rhabdomyosarcoma', Molecular Cancer Therapeutics, 24, pp. 1989 - 2004, http://dx.doi.org/10.1158/1535-7163.MCT-24-0704

Conference Abstracts

Upton D; Fajardo DC; Omari S; Porazinski S; McLean B; Schuhmacher D; Istadi A; Kothari V; Finkelstein D; Machajewski T; Rock F; Turner S; Pajic M, 2024, 'Selective targeting of integrins αVβ8 and αVβ1 within the dynamic ecosystem of pancreatic cancer to improve the overall anti-tumor response', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CA, San Diego, Vol. 84, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), CA, San Diego, 05 April 2024 - 10 April 2024, http://dx.doi.org/10.1158/1538-7445.AM2024-6575

Pajic M; McLean B; Fajardo DC; Porazinski S; Upton DH; Schuhmacher D; Istadi A; Cox T; Timpson P; Wilcock DJ; Anderson KJ; Mason H; Guisot NE; Jones CD; Phillips C; Armer R, 2024, 'Abstract 720: Combining zelasudil, a small molecule ROCK2 inhibitor, with chemotherapy or immunotherapy improves response in preclinical models of pancreatic cancer', in Cancer Research, American Association for Cancer Research (AACR), Vol. 84, pp. 720 - 720, http://dx.doi.org/10.1158/1538-7445.am2024-720

Back to profile page